News | Mammography | July 11, 2017

Volpara Solutions to Showcase Volpara Enterprise DDP Software at AHRA 2017

Package offers access to the latest versions of VolparaDensity, VolparaDose and VolparaPressure software tools in a subscription model

Volpara Solutions to Showcase Volpara Enterprise DDP Software at AHRA 2017

July 11, 2017 — Volpara Solutions Inc. will showcase its new Volpara Enterprise DDP software at the Association for Medical Imaging Management (AHRA)'s 45th Annual Meeting and Exposition, July 9-12, in Anaheim, Calif. The VolparaEnterprise Clinical Applications software package offers access to VolparaDensity, VolparaDose and VolparaPressure, in a software-as-a-service (SaaS) subscription model for the first time. Volpara Solutions will showcase its entire suite of quantitative breast imaging tools, which allow for personalized measurements of volumetric breast density, patient dose, breast compression and other factors designed to help maintain accuracy and consistent quality in breast screening.

VolparaEnterprise Clinical Applications provide quick, automated assessment of every mammography and tomosynthesis exam and produces a Volpara Scorecard for every patient with the following data:

  • VolparaDensity helps radiologists assess breast density more objectively and helps them better consider who might benefit from additional screening. The volumetric Volpara Density Grades have been shown to correlate strongly to the sensitivity of mammography and have demonstrated a strong association with the risk of developing breast cancer;
  • VolparaDose helps understand the X-ray dose delivered to the patient, based on her specific breast density. Unlike manufacturer dose, which is based on phantom measurements, VolparaDose is computed based on the patient's breast composition and provides a personalized dose measure because no two women are alike; and
  • VolparaPressure helps evaluate the effectiveness of the mammogram and better understand the patient experience. The lack of consistent guidelines regarding mammographic compression has led to wide variation in its technical execution, as well as varying levels of discomfort or pain. VolparaPressure helps monitor and optimize pressure during mammography exams, which is important to decrease the discomfort experienced by women and to optimize screening outcomes.

VolparaEnterprise software, a Microsoft Azure-based solution, delivers key performance indicators (KPIs) for hundreds of performance and quality metrics, including patient positioning, compression and equipment utilization. The software provides continuous quality assurance and performance monitoring through dynamic, interactive dashboards. Updated with every mammography or tomosynthesis (3-D mammography) exam, ConstantQuality metrics may help facilities comply with the U.S. Food and Drug Administration’s (FDA's) new Enhancing Quality Using the Inspection Program (EQUIP). 

Designed to support large or small enterprises, VolparaEnterprise software enables breast centers to perform rapid quality control checks that help optimize the productivity and efficiency of imaging resources. This in turn helps decrease costs through the reduction of retakes, increase employee effectiveness, and enhance the patient experience.

For more information: www.volparasolutions.com

Related Content

 Lunit, a leading medical AI software company, will be joining the 106th Radiological Society of North America (RSNA) this year, presenting its AI solutions for chest X-ray and mammography at partner booths.
News | Artificial Intelligence | November 24, 2020
November 24, 2020 — Lunit, a leading medical AI software company, will be joining the 106th...
ProFound AI for DBT offers superior clinical performance when compared to other commercially available breast AI systems
News | Breast Imaging | November 24, 2020
November 24, 2020 — iCAD reported that over 1,000 licenses have been sold as part of...
Densitas Inc., a global provider of A.I. technologies for digital mammography and breast screening, announced its partnership with Mammography Educators to offer the first artificial intelligence powered telehealth technologist training platform to support business continuity in mammography facilities.
News | Mammography | November 20, 2020
November 20, 2020 — Densitas Inc., a global provider of A.I.
Radiologists around the world will have access to a first-of-its-kind online breast density training tool designed to improve radiologists' ability to correctly identify women's breast density categories to comply with the Breast Imaging-Reporting and Data System (BI-RADS), thanks to a collaboration between DetectED-X and Volpara Health. 
News | Breast Density | November 19, 2020
November 19, 2020 — Radiologists around the world will have access to a first-of-its-kind online...
Reduces the complexity of reporting for screening and diagnostic MRI eams to deliver time-saving and patient safety benefits
News | MRI Breast | November 18, 2020
November 18, 2020 — ...
An interview with Professor Christiane Kuhl, M.D., director of radiology, University Hospital Aachen, Germany, on the effects on breast imaging in the COVID-19 era

Getty Images

Feature | Breast Imaging | November 12, 2020 | By Dave Fornell
The pandemic forced many elective procedures, including most areas of...
Images in a 55-year-old woman with a spiculated mass localized in the upper central quadrant (arrow in A, B, D, and E) of right breast detected with digital breast tomosynthesis (DBT) plus synthetic mammography (SM). Breast density was classified as category C with the Breast Imaging Reporting and Data System. Mass was invasive ductal carcinoma, stage I, and was estrogen and progesterone receptor positive and human epidermal growth factor receptor 2 negative. A, Image from SM in craniocaudal view. B, Single

Images in a 55-year-old woman with a spiculated mass localized in the upper central quadrant (arrow in A, B, D, and E) of right breast detected with digital breast tomosynthesis (DBT) plus synthetic mammography (SM). Breast density was classified as category C with the Breast Imaging Reporting and Data System. Mass was invasive ductal carcinoma, stage I, and was estrogen and progesterone receptor positive and human epidermal growth factor receptor 2 negative. A, Image from SM in craniocaudal view. B, Single-slice DBT image in craniocaudal view. C, Magnification of the lesion depicted in B. D, Image from SM in mediolateral oblique view. E, Single-slice DBT image in mediolateral oblique view. F, Magnification of the lesion depicted in E. Images courtesy of Radiological Society of North America

News | Breast Imaging | November 11, 2020
November 11, 2020 — ...
Hologic, Inc. announced innovative updates to its Unifi Analytics platform, a breakthrough business intelligence tool that provides mammography centers insights into technologist performance, proactive device maintenance, and business considerations.
News | Mammography | November 10, 2020
November 10, 2020 — Hologic, Inc.